OS Therapies announced that their OST-HER2 immunotherapy achieved a 71.2% three-year overall survival rate in a Phase 2b trial for metastatic osteosarcoma, significantly higher than the 45.8% survival in historical controls (p=0.002). This promising result supports early market access applications with regulators including the FDA, EMA, MHRA, and TGA, targeting commercial availability in 2027. The company also secured $3.15 million in VAT refunds and expects an additional $7.2 million in tax credits to fund a confirmatory Phase 3 trial in the UK. OST-HER2 holds multiple FDA and EMA designations, enhancing its regulatory pathway and potential for accelerated approval.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
